ADMP — Adamis Pharmaceuticals Share Price
Last Trade - 00:00- $146.41m
- $144.82m
- $16.53m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.47 | 13.07 | 15.09 | 22.11 | 16.53 | 13.68 | 10.38 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
Directors
- Richard Williams CHM (76)
- Dennis Carlo (76)
- Robert Hopkins CFO (60)
- David Marguglio SVP (49)
- Karen Daniels (67)
- David Benedicto (60)
- Ronald Moss (60)
- Howard Birndorf (70)
- Roshawn Blunt (45)
- Last Annual
- December 31st, 2020
- Last Interim
- December 31st, 2020
- Incorporated
- April 22nd, 2004
- Public Since
- August 14th, 1995
- No. of Shareholders
- 80
- No. of Employees
- 116
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 148,886,141
- Address
- 11682 El Camino Real Ste 300, SAN DIEGO, 92130-2092
- Web
- http://www.adamispharmaceuticals.com/
- Phone
- +1 8589972400
- Contact
- Mark Flather
- Auditors
- BDO USA, LLP
Latest News for ADMP
Upcoming events for ADMP
Adamis Pharmaceuticals Corp Annual Shareholders Meeting
Q3 2021 Adamis Pharmaceuticals Corp Earnings Release
Similar to ADMP
AGRIFORCE GROWING SYSTEMS ORD
NASDAQ Capital Market
ASSERTIO HOLDINGS ORD
NASDAQ Capital Market
AYTU BIOPHARMA ORD
NASDAQ Capital Market
BAIKANG BIOLOGICAL ORD
NASDAQ Capital Market
BON NATURAL LIFE ORD
NASDAQ Capital Market
FAQ
As of Today at 19:56 UTC, shares in Adamis Pharmaceuticals are trading at $0.98. This share price information is delayed by 15 minutes.
Shares in Adamis Pharmaceuticals last closed at $0.98 and the price had moved by +4.62% over the past 365 days. In terms of relative price strength the Adamis Pharmaceuticals share price has underperformed the S&P500 Index by -20.63% over the past year.
The overall consensus recommendation for Adamis Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Adamis Pharmaceuticals does not currently pay a dividend.
Adamis Pharmaceuticals does not currently pay a dividend.
Adamis Pharmaceuticals does not currently pay a dividend.
To buy shares in Adamis Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.98, shares in Adamis Pharmaceuticals had a market capitalisation of $146.41m.
Here are the trading details for Adamis Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ADMP
Based on an overall assessment of its quality, value and momentum Adamis Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Adamis Pharmaceuticals is $1.00. That is 1.69% above the last closing price of $0.98.
Analysts covering Adamis Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.24 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adamis Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -36.31%.
As of the last closing price of $0.98, shares in Adamis Pharmaceuticals were trading +9.51% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Adamis Pharmaceuticals.
Adamis Pharmaceuticals' management team is headed by:
- Richard Williams - CHM
- Dennis Carlo -
- Robert Hopkins - CFO
- David Marguglio - SVP
- Karen Daniels -
- David Benedicto -
- Ronald Moss -
- Howard Birndorf -
- Roshawn Blunt -
We do not have data on Adamis Pharmaceuticals' shareholders